NCT04826406Unknown2 期
Camrelizumab Combined Apatinib in Patients With Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors: A Single-Arm, Open-Label, Phase II Study.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
The purpose of this study is to observe and preliminary explore the efficacy and safety of the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular carcinoma (HCC) participants who have progressed following prior Immune Checkpoint Inhibitors (ICIs) treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years old, both genders.
- •Conform to the clinical diagnosis histological or cytological confirmation of HCC(hepatocellular carcinoma) and with at least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST 1.
- •Liver function status Child-Pugh score less than or equal to
- •Barcelona Clinic Liver Cancer stage Category B or C.
- •Disease progression following prior Immune Checkpoint Inhibitors (PD-1/PD-L1 or CTLA4 inhibitors) treatment for HCC, for at least 2 consecutive treatment cycles. Receipt of no more than 2 prior systemic therapies for advanced HCC.
- •Eastern Cooperative Oncology Group Performance Status of 0 or
- •Life expectancy of at least 12 weeks.
- •Adequate bone marrow, liver and renal function (without blood transfusion, without growth factor or blood components support within 14 days before enrollment).
排除标准
- •Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded.
- •The prior ICIs treatments were discontinued by intolerable adverse events.
- •Known or occurrence of central nervous system (CNS) metastases or hepatic encephalopathy.
- •Patients with tumor burden ≥50% of the liver volume or received liver transplantation.
- •Patients with clinical symptoms of ascites.
- •Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents(within 3 months): systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg.
- •Clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, or coronary artery bypass surgery, Congestive heart failure (New York heart association (NYHA) class > 2), ventricular arrhythmia which need medical intervention.
- •previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency, such as: esophageal varices, local active ulcerative lesions, gastric ulcer and duodenal ulcer, the ulcerous colitis, gastrointestinal diseases such as portal hypertension or resection of tumor with bleeding risk, etc.
- •Proteinuria ≥ (++) and 24 hours total urine protein > 1.0 g.
- •Prior systemic chemotherapy, radiotherapy, immunotherapy, hormone therapy, surgery or target therapy within 4 weeks (or 5 half-life of the drug, calculate the longer ) before the study drug administration, or any unresolved AEs > Common Terminology Criteria for Adverse Events (CTCAE) Grade
- •Prior Camrelizumab or Apatinib treatments.
研究组 & 干预措施
Camrelizumab+Apatinib
Experimental
干预措施: Camrelizumab combined Apatinib regimen (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: Up to approximately 12 months
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
次要结局
- Disease Control Rate (DCR)(Up to approximately 12 months)
- Duration of Response (DoR)(Up to approximately 12 months)
- 12-month survival rate(Up to approximately 12 months)
- Overall survival(OS)(Up to approximately 24 months)
- Safety as measured by the rate of AEs, SAEs and laboratory abnormalities(From the first assignment of informed consent form up to 90 days after the last dose)
- Time to objective response(TTR)(Up to approximately 12 months)
- Progression-free survival(PFS)(Up to approximately 12 months)
- 6-month survival rate(Up to approximately 12 months)
- 9-month survival rate(Up to approximately 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04548271Sun Yat-sen University25
已完成
2 期
Camrelizumab Combined With Apatinib for Recurrent Resistant GTNGestational Trophoblastic DiseaseNCT04047017Peking Union Medical College Hospital20
招募中
2 期
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic NeoplasiaGestational Trophoblastic NeoplasiaNCT05139095Peking Union Medical College Hospital70
尚未招募
2 期
Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaNCT05189184The First Affiliated Hospital of Zhengzhou University30
Unknown
1 期
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIbTransformed LymphomaEBV-Positive DLBCL, NosALK-Positive Anaplastic Large Cell LymphomaNCT04476459Huiqiang Huang33